Close Menu

NEW YORK – OpGen announced Tuesday it has issued a formal response to the US Food and Drug Administration's request for additional information for its Acuitas AMR Gene Panel premarket submission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.